Immediate Reactions to Monoclonal Antibodies in Clinical Hematology
PDF

Keywords

Drug Allergy
Hematology
Hypersensitivity
Infusion Reactions
Monoclonal Antibodies

Categories

How to Cite

1.
Kyriazi V. Immediate Reactions to Monoclonal Antibodies in Clinical Hematology. Integr J Med Sci [Internet]. 2016 Jan. 30 [cited 2024 Jul. 24];3:32-9. Available from: https://mbmj.org/index.php/ijms/article/view/40

Abstract

Monoclonal antibodies (MoAbs) have been widely used in clinical hematology. As foreign macro-molecules, they can cause infusional reactions during the administration or within 24 hours after the infusion, which encompass a spectrum of mechanisms. Although most of these reactions are non-allergic, are often indistinguishable from true allergic reactions mediated by IgE immunoglobulins. The diagnosis is often challenging and relies mainly on clinical criteria. They occur during the first doses, soon after the initiation of treatment. The symptoms are usually well controlled by the immediate drug discontinuation or reduction of the infusion rate. The management remains largely supportive, consisting of oxygen, intravenous fluids, bronchodilators, antihistamines and steroids. Most of MoAb protocols recommend premedication with steroids and antihistamines and gradually escalating infusion rates. Increased medical and nursing vigilance is required and resuscitative equipment should always be readily available. These events affect patients' quality of life, leading to treatment delay or discontinuation and series of tests. The decision to rechallenge the treatment depends on severity grading, clinical parameters and treatment goals. This article provides an update of MoAbs used in clinical hematology. It summarizes the pathophysiology, the diagnostic approach, the preventive measures and treatment of MoAb-related reactions.

https://doi.org/10.15342/ijms.v3i2.102
PDF

References

Kang SP, Saif MW. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer–identification, prevention, and management. J Support Oncol. 2007 Oct;5(9):451–7.

Riedl MA, Casillas AM. Adverse drug reactions: Types and treatment options. Am Fam Physician. 2003 Nov 1; 68(9):1781-90. [Accessed 15 June 2021]. Available from : https://www.aafp.org/afp/2003/1101/p1781.html

Vogel WH. Infusion reactions: Diagnosis, assessment and management. Clin J Onc Nurs. 2010 Apr;14(2):E10-21. https://doi.org/10.1188/10.cjon.e10-e21

Pio R, Corrales L, Lambris JD. The role of complement in tumor growth. Adv Exp Med Bio. 2014;772(3):229–62. https://doi.org/10.1007/978-1-4614-5915-6_11

Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014; 2014: 545493. https://doi.org/10.1155/2014/545493

Dinarello CA. Proinflammatory cytokines. Chest 2000 Aug;118(2):503–8. https://doi.org/10.1378/chest.118.2.503

Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007 May;12(5):601–9. https://doi.org/10.1634/theoncologist.12-5-601

Warrington R, Silviu-Dan F, Wong T. Drug allergy. Allergy Asthma Clin Immunol. 2018 Sep 12; 14 (Suppl 2):60. https://doi.org/10.1186/s13223-018-0289-y

Abbas AK, Lichtman AH, Pillai S. Humoral immune responses. Basic Immunology: Functions and Disorders of the Immune System. 4th edition. Philadelphia: Saunders-Elsevier; 2014. P.131–150.

Sudowe S, Rademaekers A, Kolsch E. Antigen dosedependent predominance of either direct or sequential switch in IgE antibody responses. Immunology. 1997 Jul; 91(3):464–72. https://doi.org/10.1046/j.1365-2567.1997.00268.x

Xiong H, Dolpady J, Wabl M, Curotto de Lafaille MA, Lafaille JJ. Sequential class switching is required for the generation of high affinity IgE antibodies. J Exp Med. 2012 Feb;209(2):353–64. https://doi.org/10.1084/jem.20111941

Lieberman P, Nicklas RA, Kemp SF, Oppenheimer J, Lang DM, Bernstein IL, et al. The diagnosis and management of anaphylaxis practice parameter . : 2010 update. J Allergy Clin Immunol. 2015;115(3 Suppl 2):S483–523. https://doi.org/10.1016/j.jaci.2010.06.022

Walker M, Makropoulos D, Achuthanandam R, Bugelski PJ. Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome. Curr Opin Drug Discov Devel. 2010 Jan;13(1):124–35.

Breslin S. Cytokine-release syndrome: Overview and nursing implications. Clin J Onc Nurs. 2007 Feb; 11(1 Suppl):37–42. https://doi.org/10.1188/07.cjon.s1.37-42

Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Trans Immunol. 2015 Jul 17;4(7):e39. https://doi.org/10.1038/cti.2015.14

National Institute of Health, National Cancer Insitute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; 2009. [Accessed 15 June 2021]. Available from: https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf

Brown SG, Mullins RJ, Gold MS. Anaphylaxis: Diagnosis and management. Med J Aust. 2006 Sep 4; 185(5):283–9. https://doi.org/10.5694/j.1326-5377.2006.tb00619.x

Saif MW. Hypersensitivity reactions associated with oxaliplatin. Expert Opin Drug Saf. 2006 Sep;5(5):687–94. https://doi.org/10.1517/14740338.5.5.687

Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999 Mar;17(3):791–5. https://doi.org/10.1200/jco.1999.17.3.791

Baldo BA, Pham NH. Drug Allergy. Clinical Aspects, Diagnosis, Mechanisms, Structure-Activity Relationships. 1st edition. New York: Springer; 2013.

Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.Oncologist. 2008 Jun;13(6):725-32. https://doi.org/10.1634/theoncologist.2008-0012

Scarlet C. Anaphylaxis. J Infus Nurs. Jan-Feb 2006;29(1):39–44. https://doi.org/10.1097/00129804-200601000-00008

Sala-Cunill A, Cardona V, Labrador-Horrillo M, Luengo O, Esteso O, Garriga T, et al. Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients. Int Arch Allergy Immunol. 2013;160(2):192–9. https://doi.org/10.1159/000339749

Szebeni J. Hemocompatibility testing for nanomedicines and biologicals: Predictive assays for complement mediated infusion reactions. Eur J Nanomed. 2012;4(1):33–53. https://doi.org/10.1515/ejnm-2012-0002

Simons FE, Ardusso LR, Dimov V, Ebisawa M, El-Gamal YM, Lockey RF, et al. World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol. 2013;162(3):193-204. https://doi.org/10.1159/000354543

Chung CH, Chan E, Berlin J, Gilbert J, Yarbrough W, Satinover S, et al. Cetuximab-related hypersensitivity reactions associated with pre-existing cetuximab-specific IgE antibody. J Clin Oncol. 2007; 25(18S ASCO Meeting Abstracts): 9097. [Accessed 15 June 2021]. Available from : https://ascopubs.org/doi/abs/10.1200/jco.2007.25.18_suppl.9097

Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006 Sep; 6(9):714-27. https://doi.org/10.1038/nrc1913

Shim H. One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med. 2011 Oct 31;43(10):539-49. https://doi.org/10.3858/emm.2011.43.10.063

Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20 induced apoptosis of malignant human B cells. Cancer Immunol Immunoth. 2000 Mar;48(12):673–83. https://doi.org/10.1007/s002620050016

Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signalling pathways. Cancer Res. 2000; 60(24):7170–6. [Accessed 15 June 2021]. Available From: https://cancerres.aacrjournals.org/content/60/24/7170

RITUXAN® (Rituximab) Full Prescribing Information, Genentech: U.S. Approval, 1997. [Accessed 15 June 2021]. Available from: https://www.gene.com/download/pdf/rituxan_prescribing.pdf

Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005 Oct; 31(6):456-73. https://doi.org/10.1016/j.ctrv.2005.05.007

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002 Jan 24; 346(4):235–42. https://doi.org/10.1056/nejmoa011795

Davies A, Merli F, Mihaljevic B, Siritanaratkul N, SolalCéligny P, Barrett M, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014 Mar; 15(3):343-52. https://doi.org/10.1016/s1470-2045(14)70005-1

Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol. 2012 Oct 11; 5:64. https://doi.org/10.1186/1756-8722-5-64

Glaxo Group LtdSPC. Arzerra 100mg & 1000mg concentrate for solution for infusion. UK: [Accessed 15 June 2021]. Available from: https://medikamio.com/en-gb/drugs/arzerra-1000-mg-concentrate-for-solution-for-infusion/pil

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, et al. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica. 2015 Apr;100(4):511-6. https://doi.org/10.3324/haematol.2014.118158

Osterborg A, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmen A, et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: Results from the planned interim analysis of an international pivotal trial. Blood. 2008; 112(11):328-8. https://doi.org/10.1182/blood.V112.11.328.328

Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses .Oncoimmunology. 2013 Oct 17;2(10):e26333. https://doi.org/10.4161/onci.26333

Stevens PL, Oluwole O, Reddy N. Advances and application of radioimmunotherapy in non-Hodgkin's lymphoma. Am J Blood Res. 2012;2(2):86-97.[Available 15 June 2021]. Available From: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384399/

Tomblyn M. Radioimmunotherapy for B-cell non-Hodgkin's lymphomas. Cancer Control. 2012 Jul; 19(3):196–203. https://doi.org/10.1177/107327481201900304

Zevalin FDA Prescribing Information; c2000-2016. USA; 2019.[Accessed 19 June 2021]. Available from: https://www.drugs.com/pro/zevalin.html

Podhorecka M, Markowicz J, Szymczyk A, Pawlowski J. Target therapy in hematological malignances: new monoclonal antibodies. Int Sch Res Notices. 2014 Oct 29;2014:701493.https://doi.org/10.1155/2014/701493

Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cellmediated B-cell cytotoxicity. Blood. 2010 Jun 3; 115(22):4393-402. https://doi.org/10.1182/blood-2009-06-225979

GAZYVA® (obinutuzumab) Full prescribing information: Genentech, Inc. USA, 2013. [Accessed 15 June 2021]. Available from: http://www.gene.com/download/pdf/gazyva_prescribing.pdf

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus Chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20; 370(12):1101-10. https://doi.org/10.1056/nejmoa1313984

Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene. 2007 May 28; 26(25):3644-53. https://doi.org/10.1038/sj.onc.1210380

CAMPATH® (alemtuzumab) Prescribing Information, Genzyme: USA, 2001. [Accessed 15 June 2021].Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103948s5171lbl.pdf

Keating M, Coutré S, Rai K, Osterborg A, Faderl S, Kennedy B, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma. 2004 Mar; 4(4):220-7. https://doi.org/10.3816/clm.2004.n.002

European Medicines Agency. Assessment report Adcertis-Brentuximab Vedotin; London: EMA/702390/2012. [Accessed 15 June 2021]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/adcetris-epar-public-assessment-report_en.pdf

Electronic Medicines Compendium (eMC) .SPC Adcetris® 50 mg powder for concentrate for solution for infusion; UK. [Accessed15 Jan 2016]. Available from: https://www.medicines.org.uk/emc/medicine/27173

Perini GF, Pro B. Brentuximab Vedotin in CD30+ Lymphomas. Biol Ther. 2013;3(1):15–23. https://doi.org/10.1007/s13554-013-0008-7

Mylotarg® Prescribing Information: USA, c2000-2016. [Accessed 15 Jun 2021]. Available from: http://www.drugs.com/pro/mylotarg.html

Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct1; 104(7):1442–52. https://doi.org/10.1002/cncr.21326

Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996 Dec; 33(17-18):1389-401. https://doi.org/10.1016/s0161-5890(96)00078-8

Electronic Medicines Compendium (eMC). SPC Soliris® ; UK .[Accessed 15 June 2021]. Available from: https://www.medicines.org.uk/emc/medicine/19966

Brodsky RA, Young NS, Antonioli E, Risitano MA, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008 Feb 15; 111(4):1840-47. https://doi.org/10.1182/blood-2007-06-094136

Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013 Jul;162(1):62– 73. https://doi.org/10.1111/bjh.12347

Working Group of the Resuscitation Council (UK). Emergency treatment of anaphylactic reactions: Guidelines for healthcare providers [Accessed 15 June 2021]. Available from: https://www.resus.org.uk/library/additional-guidance/guidance-anaphylaxis/emergency-treatment

Simons FER, Ardusso LRF, Bilò MB, Dimov V, Ebisawa M, El-Gamal YM, et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis.Curr Opin Allergy Clin Immunol. 2012 Aug; 12(4):389–99. https://doi.org/10.1097/aci.0b013e328355b7e4

Kemp SF, Lockey RF, Simons FE. Epinephrine: The drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy. 2008 Aug; 63(8):1061–70. https://doi.org/10.1111/j.1398-9995.2008.01733.x

Tole JW, Lieberman P. Biphasic anaphylaxis: review of incidence, clinical predictors, and observation recommendations. Immunol Allergy Clin North Am. 2007 May; 27(2):309–26. https://doi.org/10.1016/j.iac.2007.03.011

Mirakian R, Ewan PW, Durham SR, Youlten LJ, Dugué P, Friedmann PS, et al. BSACI guidelines for the management of drug allergy. Clin Exp Allergy. 2009 Jan; 39(1):43-61. https://doi.org/10.1111/j.1365-2222.2008.03155.x

Ream MA, Tunison D. Hypersensitivity reactions. In: Yasko JM, editor. Nursing management of symptoms associated with chemotherapy. Bala Cynwyd, PA: Meniscus Health Care; 2001. p. 213–24.

O’Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, et al. High incidence of cetuximab- related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007 Aug 20;25(24):3644-8. https://doi.org/10.1200/jco.2007.11.7812

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188–95. https://doi.org/10.1182/blood-2014-05-552729

Hayslip J, Fenning R. Safe administration of iodine-131 tositumomab after repeated infusionrelated reactions to rituximab. Oncologist. 2007 Mar; 12(3):338-40. https://doi.org/10.1634/theoncologist.12-3-338

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2016 Vasiliki Kyriazi

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...